Abedi Glen R, Prill Mila M, Langley Gayle E, Wikswo Mary E, Weinberg Geoffrey A, Curns Aaron T, Schneider Eileen
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia;
Division of Pediatric Infectious Diseases, University of Rochester School of Medicine and Dentistry, New York.
J Pediatric Infect Dis Soc. 2016 Mar;5(1):7-13. doi: 10.1093/jpids/piu047. Epub 2014 Jun 2.
Parainfluenza virus (PIV) is the second leading cause of hospitalization for respiratory illness in young children in the United States. Infection can result in a full range of respiratory illness, including bronchiolitis, croup, and pneumonia. The recognized human subtypes of PIV are numbered 1-4. This study calculates estimates of PIV-associated hospitalizations among U.S. children younger than 5 years using the latest available data.
Data from the National Respiratory and Enteric Virus Surveillance System were used to characterize seasonal PIV trends from July 2004 through June 2010. To estimate the number of PIV-associated hospitalizations that occurred annually among U.S. children aged <5 years from 1998 through 2010, respiratory hospitalizations from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample were multiplied by the proportion of acute respiratory infection hospitalizations positive for PIV among young children enrolled in the New Vaccine Surveillance Network. Estimates of hospitalization charges attributable to PIV infection were also calculated.
Parainfluenza virus seasonality follows type-specific seasonal patterns, with PIV-1 circulating in odd-numbered years and PIV-2 and -3 circulating annually. The average annual estimates of PIV-associated bronchiolitis, croup, and pneumonia hospitalizations among children aged <5 years in the United States were 3888 (0.2 hospitalizations per 1000), 8481 per year (0.4 per 1000 children), and 10,186 (0.5 per 1000 children), respectively. Annual charges for PIV-associated bronchiolitis, croup, and pneumonia hospitalizations were approximately $43 million, $58 million, and $158 million, respectively.
The majority of PIV-associated hospitalizations in young children occur among those aged 0 to 2 years. When vaccines for PIV become available, immunization would be most effective if realized within the first year of life.
副流感病毒(PIV)是美国幼儿因呼吸道疾病住院的第二大主要原因。感染可导致一系列呼吸道疾病,包括细支气管炎、哮吼和肺炎。已确认的人类PIV亚型编号为1至4。本研究使用最新可得数据计算了美国5岁以下儿童中与PIV相关的住院病例估计数。
利用国家呼吸道和肠道病毒监测系统的数据来描述2004年7月至2010年6月期间PIV的季节性趋势。为了估计1998年至2010年期间美国每年5岁以下儿童中与PIV相关的住院病例数,将医疗保健成本和利用项目全国住院患者样本中的呼吸道住院病例数乘以新疫苗监测网络中登记的幼儿急性呼吸道感染住院病例中PIV检测呈阳性的比例。还计算了PIV感染所致住院费用的估计数。
副流感病毒的季节性遵循特定类型的季节性模式,PIV-1在奇数年流行,PIV-2和-3每年流行。美国5岁以下儿童中与PIV相关的细支气管炎、哮吼和肺炎住院病例的年均估计数分别为3888例(每1000人中有0.2例住院)、每年8481例(每1000名儿童中有0.4例)和10186例(每1000名儿童中有0.5例)。与PIV相关的细支气管炎、哮吼和肺炎住院病例的年度费用分别约为4300万美元、5800万美元和1.58亿美元。
幼儿中大多数与PIV相关的住院病例发生在0至2岁的儿童中。当有PIV疫苗可用时,如果在生命的第一年内接种,免疫将最有效。